Physician profile
Ilkcan Cokgor
NPI 1235100603
$44,094.49
in general payments reported to CMS, 2019-2025
89 companies · $7,100 in 2025
The $7,100 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,320 · 2020: $5,679 · 2021: $6,391 · 2022: $5,753 · 2023: $6,820 · 2024: $7,031 · 2025: $7,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Education: $24.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,926.78 |
| Education | $24.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,130.38 | 2019-2025 | Qulipta, Ubrelvy, Duopa |
| Neurocrine Biosciences, INC. | $3,227.85 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $2,137.67 | 2019-2025 | Zilbrysq, Rystiggo, Briviact |
| Alexion Pharmaceuticals, INC. | $1,745.29 | 2019-2025 | Ultomiris, Soliris, Strensiq |
| Catalyst Pharmaceuticals, INC. | $1,613.55 | 2021-2025 | Fycompa |
| Emd Serono, INC. | $1,401.11 | 2019-2025 | Mavenclad |
| Biogen, INC. | $1,398.75 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Teva Pharmaceuticals USA, INC. | $1,369.99 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Avanir Pharmaceuticals, INC. | $1,353.73 | 2019-2022 | |
| Amgen INC. | $1,344.47 | 2019-2025 | Uplizna, Aimovig |
| Amneal Pharmaceuticals LLC | $1,310.73 | 2019-2025 | Rytary, Crexont |
| Pfizer INC. | $1,235.03 | 2019-2025 | |
| Eisai INC. | $1,230.21 | 2019-2025 | |
| Neurelis, INC. | $1,091.69 | 2022-2025 | Valtoco |
| Sk Life Science, INC. | $1,014.26 | 2020-2025 |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilkcan Cokgor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.